GW’s Epidiolex results are worth mentioning

Whenever one of my biotech companies have good news. It almost always makes me smile. Yesterday it was GW. The shares of GW Pharmaceuticals (GWPH) are soaring on news that its cannabis-derived drug significantly diminished the seizure amount in children with a rare form of epilepsy in a phase-three trial.

Epidiolex drug lowered the frequency of seizures by 39% in children with a form of epilepsy known as Dravet syndrome, compared to a 13% reduction in children who took a placebo. The difference was statistically significant

These results reflect a high statistical significance, after which CEO Justin Gover said “In light of this positive data, we will now request a pre-NDA meeting with the FDA to discuss our proposed regulatory submission. We also look forward with excitement to the upcoming results from the two Phase 3 trials in Lennox-Gastaut syndrome and the second pivotal trial in Dravet syndrome.” GO GW GO :-)

gw pipeline

the future studies of gw pharma

About the author

" A wise man can learn more from a foolish question than a fool can learn from a wise answer "